AAIC 2025 Abstract
Tau PET and Plasma p ‐tau217 as Independent and Synergistic Predictors of Clinical Progression in Early Symptomatic AD Patients With Amyloid and Tau Pathology
Trial in peopleBiomarkers
Abstract
Background: Blood‐based biomarkers have significant potential to aid in the diagnosis of Alzheimer's disease (AD), providing a more accessible option than cerebrospinal fluid testing or positron emission tomography (PET).
